IP Intelligence

Home | IP Intelligence

<img class="alignright wp-image-5033" src="https://ipintelligencereport.bakerhostetlerblogs.com/wp-content/uploads/sites/11/2019/09/patent-law-GettyImages-899094824_1200x630_72dpi.jpg" alt="" width="381" height="200" />

Partner Hussein Akhavannik and Counsel Fabian Koenigbauer authored an article published Dec. 19, 2019, by IAM.com. The article, “Federal Circuit Ruling Marks Out Dangers of Doctrine of Equivalents Estoppel,” discusses how the Federal Circuit’s ruling in Pharma Tech Solutions Inc. v. Lifescan Inc. underscores the importance of carefully crafting claim amendments and arguments during prosecution to avoid being precluded from enforcing a patent under the doctrine of equivalents (DOE).

<a href="https://www.iam-media.com/law-policy/federal-circuit-ruling-marks-out-dangers-doctrine-equivalents-estoppel">Read the article</a>.

Hussein Akhavannik, Fabian Koenigbauer Article Examines Lessons to Learned from “Pharma Tech” Decision